✦ LIBER ✦

The valuation of prenatal life in economic evaluations of perinatal interventions

✍ Scribed by Judit Simon; Stavros Petrou; Alastair Gray

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 93 KB
Volume: 18
Category: Article
ISSN: 1057-9230
DOI: 10.1002/hec.1375

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Perinatal interventions delivered during the prenatal period have the potential to directly impact prenatal life. The decision on when to begin ‘counting’ the life of an infant in the calculus has received little attention in previous economic evaluations of perinatal interventions. We illustrate, using data from a recent trial‐based economic evaluation of magnesium sulphate given to women with pre‐eclampsia to prevent eclampsia, how different definitions of when human life commences can have a significant impact upon cost‐effectiveness estimates based on composite outcome measures such as life years or quality‐adjusted life years gained or disability‐adjusted life years averted. Further, we suggest ways in which methods in this area can be improved. Copyright © 2008 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Economic evaluation in schistosomiasis:

Economic evaluation in schistosomiasis: valuation of health states preferences: a research note

✍ Joses Muthuri Kirigia 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB 👁 2 views

Poor countries can ill-afford ineffective health care. An effective disease intervention is one which produces a net improvement in beneficiaries' quality of life and/or increases life expectancy. Unlike developed countries, very little research has been done in developing countries on the measures

Economic evaluation of prenatal screenin

Economic evaluation of prenatal screening for Down syndrome in the U.S.A.

✍ Tryfon Beazoglou; Dennis Heffley; John Kyriopoulos; Anthony Vintzileos; Peter Be 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB 👁 2 views

Maternal serum screening for Down syndrome involves biochemical tests such as alpha-fetoprotein ( FP), human chorionic gonadotrophin (hCG) and unconjugated oestriol (uE 3 ), either alone or in combination, that have variable detection and false-positive rates. Choosing a screening protocol requires

The efficiency frontier approach to econ

The efficiency frontier approach to economic evaluation of health-care interventions

✍ J. Jaime Caro; Erik Nord; Uwe Siebert; Alistair McGuire; Maurice McGregor; David 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB 👁 1 views

## Abstract __Background__: IQWiG commissioned an international panel of experts to develop methods for the assessment of the relation of benefits to costs in the German statutory health‐care system. __Proposed methods__: The panel recommended that IQWiG inform German decision makers of the net co

The distribution problem in economic eva

The distribution problem in economic evaluation: income and the valuation of costs and consequences of health care programmes

✍ Cam Donaldson; Stephen Birch; Amiram Gafni 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 2 views

To date, a common view in the health economics literature is that the applicability of cost-benefit analysis (CBA) is limited, due to the distribution problem which underlies its main method of valuation (e.g. willingness to pay). One view is that cost effectiveness analysis (CEA) overcomes these pr

The increasing role of health economic e

The increasing role of health economic evaluations in drug development

✍ Lieven Annemans; Irina Cleemput; Steven Simoens; Francis Arickx; Frank Hulstaert 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 1 views

Something rotten in the state of clinica

Something rotten in the state of clinical and economic evaluations?

✍ Nick Freemantle; Alan Maynard 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 480 KB